Brief ReportEGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
Keywords
Cited by (0)
Disclosure: Dr. O'Toole reports personal fees from Pfizer, Astra Zeneca, Merck, Bristol-Myers Squibb, and Roche outside the submitted work. Dr. Boyer reports grants, personal fees, and nonfinancial support from Pfizer; grants and personal fees from Merck Sharpe and Dohme and Bristol-Myers Squibb; grants and nonfinancial support from Boehringer Ingelheim and Astra Zeneca; and grants from Amgen and Clovis outside the submitted work. Dr. Cooper reports personal fees from Astra-Zeneca, Merck Sharpe and Dohme, Bristol-Myers Squibb, and Pfizer outside the submitted work. Dr. Kao reports nonfinancial support from Bristol-Myers Squibb and Boehringer Ingelheim, personal fees and nonfinancial support from Roche and AstraZeneca, and personal fees from Pfizer outside the submitted work. The remaining authors declare no conflict of interest.